OpenAI announced ChatGPT Health, a feature that lets users connect medical records for personalized advice. This comes just days after a report linked a teen’s fatal overdose to erroneous ChatGPT guidance. The company insists it’s for support, not diagnosis.
Wabash National Corporation is permanently closing plants in Minnesota and Indiana, eliminating 270 positions. The move follows a 17.8% year-over-year drop in quarterly sales. Costs for the shutdown are estimated between $15 and $20 million.
A year-long series from CRN highlights five critical leadership lessons from women in cybersecurity. The core message? Strong security is built on people-first leadership, not just technical control.
A new review of studies finds that people who stop taking GLP-1 obesity medications like semaglutide regain weight quickly, about 1.8 pounds per month. This suggests many may need to stay on the drugs long-term to maintain results.
The public has until January 21 to comment on a massive R76-billion revenue adjustment for Eskom, which could force electricity tariffs up by about 10.5% this year. The move follows legal challenges over a lack of transparency in previous decisions.
In a stunning rebuke, Tesla investors voted to reinstate Elon Musk’s $56 billion compensation plan. They also rejected advice from major proxy firms, signaling a major shift in corporate governance.
The University of Southern Denmark is teaming up with Danfoss and HPE to build a new AI supercomputer. It will use 128 Nvidia Blackwell GPUs and aims to be a model for sustainable computing by reusing waste heat.
China’s top market watchdog is cracking down on potential collusion in the booming solar sector. Six leading manufacturers have been summoned and told to submit rectification plans by January 20.
Bitcoin mining hardware maker Canaan is launching a two-year pilot in Manitoba, Canada, to recover waste heat from its servers. The 3MW facility will use 360 liquid-cooled machines to preheat water for a commercial greenhouse, targeting year-round tomato cultivation.
Alpenglow Biosciences is moving its 3D imaging tech from research labs to patient diagnostics. A new partnership with lab network PathNet aims to modernize prostate and bladder cancer testing. The startup also secured fresh funding and is working towards regulatory approval next year.
